The lectin-like domain of thrombomodulin interferes with complement activation and protects against arthritis. - Wikidata - wikimedia - TriplyDB

The lectin-like domain of thrombomodulin interferes with complement activation and protects against arthritis.

The lectin-like domain of thrombomodulin interferes with complement activation and protects against arthritis.

http://www.wikidata.org/entity/Q45861457

about

Targeting HMGB1 in inflammation Thrombomodulin mutations in atypical hemolytic-uremic syndrome.Controlling coagulation dysregulation in xenotransplantation.The efficacy of recombinant human soluble thrombomodulin for the treatment of shiga toxin-associated hemolytic uremic syndrome model mice.Thrombomodulin as an intravascular safeguard against inflammatory and thrombotic diseases.Differential gene expression in thrombomodulin (TM; CD141)(+) and TM(-) dendritic cell subsets Thrombomodulin is a determinant of metastasis through a mechanism linked to the thrombin binding domain but not the lectin-like domain.Human thrombomodulin knock-in mice reveal differential effects of human thrombomodulin on thrombosis and atherosclerosis.Anti-inflammatory effect of recombinant thrombomodulin for fulminant hepatic failure.The role of thrombomodulin lectin-like domain in inflammation Novel therapeutic targets for preserving a healthy endothelium: strategies for reducing the risk of vascular and cardiovascular disease HMGB1 is a therapeutic target for sterile inflammation and infection.Systemic TNF blockade does not modulate synovial expression of the pro-inflammatory mediator HMGB1 in rheumatoid arthritis patients--a prospective clinical study.Maternal Par4 and platelets contribute to defective placenta formation in mouse embryos lacking thrombomodulin.Lectin-like domain of thrombomodulin binds to its specific ligand Lewis Y antigen and neutralizes lipopolysaccharide-induced inflammatory response.Myeloid thrombomodulin lectin-like domain inhibits osteoclastogenesis and inflammatory bone loss IL-32-dependent effects of IL-1beta on endothelial cell functions High-mobility group box protein 1 (HMGB1): an alarmin mediating the pathogenesis of rheumatic disease Therapeutic modulation of coagulation and fibrinolysis in acute lung injury and the acute respiratory distress syndrome Endothelium--role in regulation of coagulation and inflammation.Immunomodulatory therapy for sepsis: an update.HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease.Recombinant thrombomodulin of different domains for pharmaceutical, biomedical, and cell transplantation applications.The role of platelets in coagulation dysfunction in xenotransplantation, and therapeutic options.High-mobility group box-1 in sterile inflammation.The coagulation system in melioidosis: from pathogenesis to new treatment strategies.Oxaliplatin retains HMGB1 intranuclearly and ameliorates collagen type II-induced arthritis.Membrane-associated CD93 regulates leukocyte migration and C1q-hemolytic activity during murine peritonitis.Negative regulation of the inflammasome: keeping inflammation under control.Human thrombomodulin regulates complement activation as well as the coagulation cascade in xeno-immune response.HMGB1, IL-1α, IL-33 and S100 proteins: dual-function alarmins Effects of a novel peptide derived from human thrombomodulin on endotoxin-induced uveitis in vitro and in vivo.Proximate Mediators of Microvascular Dysfunction at the Blood-Brain Barrier: Neuroinflammatory Pathways to Neurodegeneration Immunomodulatory drugs regulate HMGB1 release from activated human monocytes.Thrombomodulin domain 1 ameliorates diabetic nephropathy in mice via anti-NF-κB/NLRP3 inflammasome-mediated inflammation, enhancement of NRF2 antioxidant activity and inhibition of apoptosis.Complement 3 is involved with ventilator-induced lung injury.Innate immunity and coagulation.Liposomal formulations of thrombomodulin increase engraftment after intraportal islet transplantation.Characterization of soluble thrombomodulin levels in patients with stage 3-5 chronic kidney disease.Thrombomodulin's lectin-like domain reduces myocardial damage by interfering with HMGB1-mediated TLR2 signalling.

P2860

Q28266138-29BD17C4-EAF1-4696-A874-3FD1FDD37026 Q33385474-24027D33-B612-4519-9533-07FF88460CD1 Q33394542-2E322FAE-3B6A-47B6-86AC-8355FDE189F2 Q33420531-B5D565F3-7980-4AB9-B14E-5660013B5CCE Q34501341-D00994F9-546F-42E3-90AD-751F118BD7B8 Q34979529-7AD430A2-C88E-4753-B5AF-39F2A99195CC Q35212413-712586FA-A98B-47A3-A44C-A36419E7F5CF Q35457562-38D283A1-99E9-40FD-A75A-28BC7169C199 Q35843130-92061543-1046-462E-B18F-8B10F7DB190E Q35927779-4160E2E9-13FE-4961-BEB7-A5DD4D2CB0C7 Q35930091-747620B3-8AB9-49AA-89AC-38FF4810A8BE Q35953553-25D6D5BE-D785-4941-B9A3-A34AA7868296 Q36755051-EFE43449-6D0C-4B9D-891C-DBFA01370FE0 Q36787588-0AD7A5AD-7C81-4E50-8F45-AE8128047F5A Q36948577-C1EB0DAB-F144-4C4D-AEDC-B5D39E0067A0 Q37015012-726A6129-010C-43CD-8E0E-382D3A1EA0C5 Q37129422-99C6C8D6-A997-4276-8AA6-66D452530D71 Q37206315-4C73ED76-38F3-4F62-8D0B-9762277C1E30 Q37852747-2588C5D4-D302-470D-908F-6576B7C38090 Q37918456-3168282B-D030-4F4D-82DA-34CC508A9C32 Q37949639-94A1B57B-508D-498E-AB67-8D96279D4889 Q37980335-17A15780-52AB-4F59-A2BC-13DA54BB5CDA Q38117276-2406029A-E0F3-4763-BB3D-13D6C5458B28 Q38191251-57B242EC-FE32-4F16-826B-0954314D649F Q38220792-1452037A-6849-4985-BAD4-1943DDA7F61F Q38222979-6C27CE30-8B40-4412-96F8-B7D04A6EAB15 Q38274480-BC5E1F20-EFE7-4B1D-BD27-3863752A8061 Q38361924-37EF7A00-8CA8-4E47-9E72-FA7BB8F98E96 Q38423405-F45FB149-26DD-4100-A5DB-2A9AF0D240D1 Q38852483-BB660013-669A-4908-9D90-884526A77E11 Q38939435-CE5F8F40-670B-49FB-BE89-F8D565C7EF37 Q39457809-4F070254-B041-4AC1-9147-E74DDDEBB555 Q41613567-414E64A5-E6B5-4416-9443-E2B4FC05CE00 Q41855892-B88F76C2-1DAF-4BB0-9546-9AAA0CD75A5E Q42250365-CDEF5EB0-88F2-43C0-B18E-7A1BECA88412 Q42379523-50CBD1F9-B487-4214-AE7B-F1122EDAA3EB Q42856952-5ED7273E-44A9-4DAC-A2B2-A0F252D51716 Q43002071-85EDE9B1-598E-46C3-84E6-DD91A8FE27B7 Q44348501-16B5D46D-A20B-46AF-86EA-7573F2F6221A Q45858876-BE77BD38-D634-4029-8286-7692D71C6D76

P2860

The lectin-like domain of thrombomodulin interferes with complement activation and protects against arthritis.

http://www.wikidata.org/entity/Q45861457

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh-hant

name

The lectin-like domain of thro ...... nd protects against arthritis.

@en

The lectin-like domain of thro ...... nd protects against arthritis.

@nl

type

label

The lectin-like domain of thro ...... nd protects against arthritis.

@en

The lectin-like domain of thro ...... nd protects against arthritis.

@nl

prefLabel

The lectin-like domain of thro ...... nd protects against arthritis.

@en

The lectin-like domain of thro ...... nd protects against arthritis.

@nl

P1433

Q45861457-7020C665-4763-4823-8EB1-15CA436A4731

P1476

Q45861457-2D3E64E9-D5B7-4768-ADE7-6AE4CF700ABE

P2093

Q45861457-393E8937-3D8C-4829-B5D3-F60FFB6F8E57

Q45861457-A175988B-50FB-4FD8-9302-DE569D009C88

Q45861457-C294BA51-DBBF-4160-8F28-D06554D30691

Q45861457-DD36EC6D-9D89-46B8-A98B-0D2D43A58B99

Q45861457-F7447FF1-954E-4B64-9DB1-9042A6E791B6

P2860

Q45861457-160F5622-B15B-496F-86E9-D280C1FAE84E

Q45861457-19884CBF-1E6C-4F9A-AEEE-44E35921883A

Q45861457-1C22010A-13E9-4C66-B881-0ABF5496A0D4

Q45861457-1E419A76-EAFD-408B-BB07-DA683B2FA195

Q45861457-25138FF6-A330-4B57-938E-3F190C246574

Q45861457-254D78D4-4E4F-429F-9BB8-F453CE86E4B1

Q45861457-2846E305-805B-47D4-B029-4B6CDB4B4804

Q45861457-2EAE061D-3D82-43FD-B923-21C3763E01F0

Q45861457-3069E3D6-60EE-4C82-8777-2022847615A7

Q45861457-375CF062-3998-4B34-B0AE-A739C2A32B6D

P304

Q45861457-279DF431-83C3-4D14-9D76-AD89E490FD57

P31

Q45861457-2F7E48EB-F5CF-49B6-B03E-3EDCECCC8610

P356

Q45861457-679446B1-625C-4B44-900E-7DEDCC95BE64

P433

Q45861457-92377E9B-7BEE-4B8F-8FF6-668D2B87E29A

P478

Q45861457-50B8CB10-E80F-496D-B032-BA735B8205EC

P50

Q45861457-10CB8393-ED35-42FD-A06C-FF1C3BB6E681

Q45861457-4100F52B-AAD1-4551-A186-BF49A41ACA6D

Q45861457-814B8FCB-8E36-4E52-B8BA-CFE4C116BF21

P577

Q45861457-BA5C190B-FEF4-43D7-993C-BD213028E68D

P5875

Q45861457-D5C4CD74-4B53-4E62-8EE2-F95E22CC0D89

P698

Q45861457-53A71D25-0CC0-45ED-860D-CAB83BCF5731

P356

J.1538-7836.2006.02033.X

P1433

Journal of Thrombosis and Haemostasis

P1476

The lectin-like domain of thro ...... and protects against arthritis

@en

P2093

Collen D

http://www.w3.org/2001/XMLSchema#string

Daha MR

http://www.w3.org/2001/XMLSchema#string

De Vriese A

http://www.w3.org/2001/XMLSchema#string

Van de Wouwer M

http://www.w3.org/2001/XMLSchema#string

Waelkens E

http://www.w3.org/2001/XMLSchema#string

P2860

Elevation of activated protein C in synovial joints in rheumatoid arthritis and its correlation with matrix metalloproteinase 2

Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety

Efficient selection for high-expression transfectants with a novel eukaryotic vector

Thrombomodulin-protein C-EPCR system: integrated to regulate coagulation and inflammation

Modulation of the classical pathway C3 convertase by plasma proteins C4 binding protein and C3b inactivator

From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins.

Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease.

Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor.

Inactivation of C3a and C5a octapeptides by carboxypeptidase R and carboxypeptidase N.

Proteases of the complement system.

P304

1813-1824

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1538-7836.2006.02033.X

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

Edward M. Conway

Stephane Plaisance

P577

2006-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6907857

http://www.w3.org/2001/XMLSchema#string

P698

16879225

http://www.w3.org/2001/XMLSchema#string